Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 78,553 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the sale, the chief executive officer now owns 267,629 shares of the company’s stock, valued at approximately $44,150,756.13. The trade was a 22.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Friday, November 15th, Steven Leonard Chapman sold 4,728 shares of Natera stock. The shares were sold at an average price of $146.41, for a total value of $692,226.48.
• On Monday, October 28th, Steven Leonard Chapman sold 3,960 shares of Natera stock. The shares were sold at an average price of $118.21, for a total value of $468,111.60.

Natera Price Performance

Natera stock opened at $171.82 on Friday. Natera, Inc. has a 12 month low of $62.96 and a 12 month high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The business’s 50 day simple moving average is $165.35 and its 200 day simple moving average is $135.41. The company has a market cap of $22.68 billion, a price-to-earnings ratio of -97.63 and a beta of 1.65.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. During the same quarter in the prior year, the business earned ($0.95) earnings per share. Natera’s revenue for the quarter was up 63.9% on a year-over-year basis. Sell-side analysts forecast that Natera, Inc. will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Natera

Several institutional investors have recently bought and sold shares of the company. Blue Trust Inc. raised its holdings in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 97 shares during the period. Quarry LP raised its holdings in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares during the period. Versant Capital Management Inc raised its holdings in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 166 shares during the period. Covestor Ltd raised its holdings in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares during the period. Finally, GAMMA Investing LLC raised its holdings in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 106 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on NTRA shares. The Goldman Sachs Group raised their target price on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Leerink Partners raised their target price on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Guggenheim raised their target price on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 17th. Barclays started coverage on Natera in a research note on Thursday. They set an “overweight” rating and a $200.00 price target for the company. Finally, Piper Sandler lifted their price target on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $162.94.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.